(Q39209990)

10 September 2017

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored (English)

1 reference

10 September 2017

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hertzel C. Gerstein

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Rury Holman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Marc A Pfeffer

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

13 March 2014

1 reference

The Lancet: Diabetes & Endocrinology

10 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

843-851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731668%20AND%20SRC:MED&resulttype=core&format=json

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular safety and diabetes drug development

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

1 reference

7 January 2021

Clinical practice. Systolic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Diabetes, left ventricular systolic dysfunction, and chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Diabetes: a driver for heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Mortality rates in trials of subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Strategies for multivessel revascularization in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular events during differing hypertension therapies in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Adjudication of serious heart failure in patients from PROactive

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Dipeptidyl peptidase IV and mortality after an acute heart failure episode

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Cardiovascular effects of gliptins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Myocardial substrate metabolism in the normal and failing heart

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970031-2

7 January 2021